Memorial Hospital Research Laboratories

The Charles Rudin Lab

Share
Print
Back to Top

Research

Charles M. Rudin, MD, PhD
Charles M. Rudin, MD, PhD


Professor

Physician-scientist Charles M. Rudin, Chief of the Thoracic Oncology Service, leads research that focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models including patient-derived xenografts. These studies are integrated with early phase clinical trials.

The Charles Rudin Lab

Featured News

In the Clinic
Physician-scientist Charles Rudin
Unexpected Finding Reveals New Target for Aggressive Form of Lung Cancer

Michael Postow, Nitya Raj and Triparna Sen
MSK Leaders Recognized in the 40 Under 40 in Cancer Class of 2020

Charles Rudin with lab member
ASCO 2020: Advances in the Treatment of Small-Cell Lung Cancer

View All Featured News

Publications

Hulton, C. H., Costa, E. A., Shah, N. S., Quintanal-Villalonga, A., Heller, G., de Stanchina, E., Rudin, C. M. & Poirier, J. T. Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics. Nat Cancer 1, 359-369 (2020).

Wohlhieter, C. A., Richards, A. L., Uddin, F., Hulton, C. H., Quintanal-Villalonga, A., Martin, A., de Stanchina, E., Bhanot, U., Asher, M., Shah, N. S., Hayatt, O., Buonocore, D. J., Rekhtman, N., Shen, R., Arbour, K. C., Donoghue, M., Poirier, J. T., Sen, T. & Rudin, C. M. Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer. Cell Rep 33, 108444 (2020).

Quintanal-Villalonga, A., Chan, J. M., Yu, H. A., Pe’er, D., Sawyers, C. L., Sen, T. & Rudin, C. M. Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol 17, 360-371 (2020).

Taniguchi, H., Sen, T. & Rudin, C. M. Targeted Therapies and Biomarkers in Small Cell Lung Cancer. Front Oncol 10, 741 (2020).

View All Publications

People

Charles M. Rudin, MD, PhD

Charles M. Rudin, MD, PhD



Professor

  • Physician-scientist Charles Rudin focuses on the development and testing of novel therapeutic approaches to lung cancer in preclinical models.
  • MD, PhD, University of Chicago Pritzker School of Medicine
rudinc@mskcc.org
Email Address
View physician profile
Physician profile

Members

Triparna Sen, PhD
Triparna Sen

Assistant Attending/Lab Co-Director

Viola Allaj
Viola Allaj

Senior Research Technician

Metamia Ciampricotti
Metamia Ciampricotti

Research Fellow

Corrin Wohlhieter
Corrin Wohlhieter

Graduate Student

Nisarg Shah
Nisarg Shah

Senior Research Assistant/Lab Manager

Joseph Chan
Joseph Chan

Thoracic Oncology Fellow

Andrew Chow
Andrew Chow

Assistant Attending, Thoracic Oncology Service

Emily Costa

Graduate Student

W. Victoria Lai
Victoria Lai

Assistant Attending, Thoracic Oncology Service

Hirokazu Taniguchi
Hirokazu Taniguchi

Research Fellow

Fathema Uddin
Fathema Uddin

Research Technician

Álvaro Quintanal Villalonga
Álvaro Quintanal Villalonga

Research Fellow

Rebecca Caeser
Rebecca Caeser

Research Fellow

Kelly Clarke

Portfolio Manager

Chayan De

Research Fellow

Vidushi Durani
Vidushi Durani

Graduate Student

Parvathy Manoj
Parvathy Manoj

Research Technician

Evelyn Nguyen
Evelyn Nguyen

Graduate Student

Kathryn M. Tully
Kathryn M. Tully

Graduate Student

Lab Alumni
Eric Gardner
Eric Gardner

Postdoctoral Research Fellow, Harold Varmus Lab, WCMC

Christopher Hulton, BS, MS
Christopher Hulton

Research Scientist at C4 Therapeutic, Watertown, Massachusetts

James Laird
James Laird

Medical Resident, Yale School of Medicine

Pictured: Benjamin Lok
Benjamin Lok

Clinician-Scientist, Princess Margaret Cancer Centre and Assistant Professor of Radiation Oncology, University of Toronto

Linde Miles
Linde Miles

Postdoctoral Research Fellow, Ross Levine Lab, MSKCC

Lab Affilations

Open Positions

Career Opportunities

Apply now

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles M. Rudin discloses the following relationships and financial interests:

  • AbbVie
    Provision of Services
  • Amgen
    Provision of Services (uncompensated)
  • Ascentage Pharma
    Provision of Services
  • Astra Zeneca
    Provision of Services
  • Bridge Medicines
    Provision of Services (uncompensated)
  • Celgene
    Provision of Services
  • Chugai Pharmaceuticals
    Provision of Services
  • Daiichi Sankyo
    Provision of Services
  • Elucida Oncology
    Provision of Services (uncompensated)
  • Genentech
    Provision of Services
  • Harpoon Therapeutics, Inc.
    Provision of Services
  • Loxo Oncology
    Provision of Services
  • MORE Health, Inc
    Provision of Services
  • Roche
    Provision of Services
  • SynDevRx Inc
    Provision of Services

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures